Welcome to our dedicated page for Castle Biosciences SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Castle Biosciences, Inc. filings document the regulatory record for a Delaware molecular diagnostics company with common stock listed on the Nasdaq Global Market under CSTL. Recent Form 8-K filings report quarterly and annual operating results, preliminary performance updates, and Regulation FD slide presentations tied to management communications.
The company’s proxy materials cover annual meeting matters, executive compensation, director elections, stockholder voting procedures, and governance disclosures. Other material-event filings document amendments to bylaws, including provisions related to stockholder meetings, director nominations, and board governance, alongside standing disclosures on registered securities and exchange listing status.
CASTLE BIOSCIENCES INC Chief Operating Officer Kristen M. Oelschlager reported an open-market sale of 8,587 shares of common stock at a weighted-average price of $20.71 per share on June 16, 2026. The sale was executed as a planned transaction under a Rule 10b5-1 trading plan adopted on March 17, 2026.
Following this sale, she holds 30,460 shares of common stock directly and 97,251 shares indirectly through The Fritz Shorter Trust, where she and her spouse serve as trustees and beneficiaries.
CASTLE BIOSCIENCES INC director and CEO Derek J. Maetzold reported a mix of option exercises and pre-planned share sales involving his direct and trust-related holdings. He exercised stock options to acquire 550 shares of common stock at $2.39 per share, increasing his direct holdings before selling shares.
Entities associated with him, including several 2018 and 2020 family trusts, sold a combined 4,172 shares of common stock in open-market transactions at a weighted-average price of $20.66 per share. These sales were carried out under a Rule 10b5-1 trading plan adopted on December 3, 2025, indicating the trades were pre-scheduled. Following the transactions, Maetzold holds 21,479 shares directly and various additional indirect positions through multiple grantor retained annuity and remainder trusts.
CSTL filed a Rule 144 notice reporting proposed sales tied to an exercise of stock options. The filing lists 4,152 shares associated with the option exercise dated 06/16/2026 and also shows 25,759 restricted and performance stock units with a 12/31/2025 date.
Castle Biosciences CEO Derek J. Maetzold reported a mix of option exercises and share sales in Castle Biosciences Inc. common stock. He exercised stock options to acquire 6,214 shares at a price of $2.3900 per share and sold 9,836 shares in open-market transactions at a weighted-average price of $20.8570 per share.
Part of the sales came from entities such as The Maetzold Descendants 2020 Trust, the Derek Maetzold 2020 Irrevocable Trust and several 2018 remainder trusts, while a portion was from his direct holdings, which totaled 21,479 shares after these transactions. All sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.
The filing reports multiple Rule 144-related dispositions of common stock by entities and trusts associated with Derek Maetzold, with sizeable blocks sold across March–May 2026. Representative transactions include a sale of 23,179 shares on 03/12/2026 and repeated smaller trust sales; proceeds are shown per trade.
Olson Tiffany reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Tiffany Olson received a grant of 11,766 Restricted Stock Units as equity compensation. Each RSU represents the right to receive one share of Castle Biosciences common stock at no purchase price.
The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately before the company’s next Annual Meeting of Stockholders following the grant date. After this award, Olson holds 11,766 RSUs directly, and the filing shows no additional option or derivative positions.
Goldberg Ellen reported acquisition or exercise transactions in this Form 4 filing.
CASTLE BIOSCIENCES INC director Ellen Goldberg received a grant of 11,766 Restricted Stock Units (RSUs). Each RSU represents one share of the company’s common stock, so this award covers 11,766 shares. Following the grant, she holds 11,766 RSUs directly.
The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. This is a compensation-related equity award, not an open‑market share purchase or sale.
Harrison Miles reported acquisition or exercise transactions in this Form 4 filing.
CASTLE BIOSCIENCES INC director Miles Harrison received a grant of Restricted Stock Units. On May 28, 2026, he was awarded 11,766 RSUs, each representing the right to receive one share of the company’s common stock. These RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. Following this award, his reported derivative holdings from this grant total 11,766 RSUs held directly.
Cotton Rodney reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Rodney Cotton received a grant of 11,766 Restricted Stock Units. Each RSU represents the right to receive one share of Castle Biosciences common stock. The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next annual meeting of stockholders following the grant date.
Caple Kim reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Kim Caple received a grant of 11,766 Restricted Stock Units (RSUs) linked to the company’s common stock. Each RSU represents one share of common stock, for a total underlying amount of 11,766 shares. The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. After this grant, Caple’s reported derivative holdings from this award total 11,766 RSUs.